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Abstract
Acute rheumatic fever (ARF) and rheumatic heart disease are serious autoimmune sequelae to infections with Streptococcus
pyogenes. Streptococcal M-proteins have been implicated in ARF pathogenesis. Their interaction with collagen type IV (CIV)
is a triggering step that induces generation of collagen-specific auto-antibodies. Electron microscopy of the protein
complex between M-protein type 3 (M3-protein) and CIV identified two prominent binding sites of which one is situated in
the CB3-region of CIV. In a radioactive binding assay, M3-protein expressing S. pyogenes and S. gordonii bound the CB3-
fragment. Detailed analysis of the interactions by surface plasmon resonance measurements and site directed mutagenesis
revealed high affinity interactions with dissociation constants in the nanomolar range that depend on the recently
described collagen binding motif of streptococcal M-proteins. Because of its role in the induction of disease-related collagen
autoimmunity the motif is referred to as ‘‘peptide associated with rheumatic fever’’ (PARF). Both, sera of mice immunized
with M3-protein as well as sera from patients with ARF contained anti-CB3 auto-antibodies, indicating their contribution to
ARF pathogenesis. The identification of the CB3-region as a binding partner for PARF directs the further approaches to
understand the unusual autoimmune pathogenesis of PARF-dependent ARF and forms a molecular basis for a diagnostic
test that detects rheumatogenic streptococci.
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Introduction
Acute rheumatic fever (ARF) can occur as a sequela to
inadequately treated infection with Streptococcus pyogenes (group A
streptococcus (GAS)), and it is one of the most serious outcomes of
streptococcal disease [1]. ARF, which often develops into
rheumatic heart disease (RHD), remains a major cause of
cardiovascular disease that is affecting the young, particularly in
developing countries [1,2]. Recent data estimate that more than
15 million people suffer from RHD, more than 0.5 million acquire
ARF each year, and about 0.25 million deaths annually are
directly attributable to either ARF or RHD [2].
Although the exact pathogenesis of ARF remains elusive, it is
known to be the result of autoimmune responses triggered by
streptococcal infection [1,3]. Type IV collagen (CIV) is a major
constituent of endothelial cell basement membranes, and is a
factor which is involved in a series of autoimmune syndromes [4].
Certain streptococcal strains are able to bind collagen and this
interaction is important for virulence [5–7]. Six genetically distinct
alpha-chains of CIV exist, which assemble into hetero-trimers of
different compositions. These molecules consist of a triple-helical
domain that is flanked by non-collagenous domains, the N-
terminal 7S domain and the C-terminal globular domain, referred
to as NC1 (for schematic representation see [8]). Both non-
collagenous domains are involved in the formation of hexagonal
networks that are the typical assembly of CIV in the basement
membrane. CIV binds to cells by interacting with a1b1 and a2b1
integrins via a region that is located approximately 100 nm from
the N-terminus and that is known as cyanogen bromide fragment
3 (CB3) [9,10].
A major virulence factor of S. pyogenes is the M-protein. This
surface protein exists in more than 100 serotypes which is the
consequence of a high sequence variability in the N-terminal part of
the protein. The rheumatogenicity of S. pyogenes strains has been
shown to correlate with certain M serotypes, suggesting that the M-
protein plays a key role in the pathogenesis of ARF [11]. One such
rheumatogenic type is the M3 serotype. Immunization of mice with
M3-protein leads to the formation of CIV auto-antibodies, which
are also found in the sera of patients with ARF or RHD [6] and our
group has shown previously that collagen-binding M-proteins like
the M3-protein bind and aggregate CIV via an octa-peptide motif
that is referred to as PARF (peptide associated with rheumatic fever)
[5]. The observation that the collagen autoimmunity that is caused
by PARF does not depend on molecular mimicry [5] motivated
further investigations on the molecular details of the interaction
between M-proteins and CIV. The herein described insights will
help us to elucidate the induction of ARF-related collagen
autoimmunity, which to date is poorly understood.
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Characterization of the interaction between CIV and M3-
protein
Examination of complexes between CIV and M3-protein by
means of rotary shadowing electron microscopy gave insights into
the molecular basis of the interaction. Consistent with previous
observations on the complex of FOG and collagen I [7] the M-
protein appeared as a thread-like structure with a globular end
that is formed by the N-terminal GST-tag. As shown in Figure 1,
the N-terminal end of the M3-protein (arrows) forms contacts with
the CIV-molecule. M3-protein bound to two prominent sites on
the CIV-molecule, 20 nm and 100 nm distant from the 7S region
(arrow heads). The latter site corresponds to the position of the CB3
region of CIV. In a pull-down assay glutathion sepharose beads
were loaded with GST-tagged M-proteins type M3 and M18,
respectively. While M3-protein bound
125I-labeled CB3, M18-
protein produced radioactivity counts at the level of the GST-
loaded glutathion sepharose that was used as a negative control
(Fig. 2A). Surface bound M3-protein on SGO M3 also bound high
amounts of both CIV and CB3 ($80% of the
125I-labeled ligand)
(Fig. 2B), as seen in comparison with the wild type S. gordonii that
showed no binding to either full length CIV or the CB3-fragment.
When M3-protein was subjected to surface plasmon resonance
analysis using either full length CIV or the CB3-fragment of CIV
as an immobilized ligand it showed concentration dependent
binding to both CIV (Fig. 2C) and CB3 (Fig. 2D), with apparent
dissociation constants of Kd=5 610
29 M and Kd=6 610
28 M,
respectively. Taken together the results demonstrate a direct and
specific interaction between M3-protein and CIV and identify a
binding site in the CB3-region of CIV that exhibits a considerable
affinity. Expression of M3-protein on its surface is sufficient to
transform the S. gordonii strain into a bacterium with a high binding
capacity for CIV and CB3.
PARF is the binding motif for CB3
Recently, we have identified the consensus motif that is
common to all collagen binding streptococcal M-proteins and
could demonstrate that it has a crucial role in the pathogenesis of
rheumatic fever [5]. Its consensus sequence AXYLZZLN is
designated PARF (peptide associated with rheumatic fever). To
test its role in binding to CB3, dot-blot experiments with wild type
M-protein and a set of variants with mutations in PARF [5] were
conducted. The results, which are summarized in figure 3, widely
paralleled previous ones on full length CIV [5], mutants with a
defective PARF (with substitutions in Ala
58, Tyr
60, Leu
61, Leu
64,
Asn
65, LND
66 or YL
61) did not bind to CB3, whereas mutations
outside of PARF (Glu
56, Asp
66) did not affect CB3 binding (Fig. 3).
Hence, an intact PARF-motif in the M-protein is essential for
efficient binding to CB3.
M3-protein induces autoimmunity against CB3
Immunization of mice with either full length M3-protein [6]
or the type specific collagen binding N-terminal part of M3-
protein (M3.5) [5] leads to the induction of CIV auto-immunity.
To examine the contribution of the CB3-region in the elicitation
of the immune response, titers of CB3-reactive antibodies in the
sera of mice immunized with M3.5 were measured and found to
be significantly elevated as compared to buffer controls
(P=0.0085) (Fig. 4A). All murine sera were reactive against
CIV and had antibodies against the CB3-fragment (Fig. 4B).
Analysis of human sera from clinical cases of collagen-associated
ARF/RHD revealed elevated titers against CB3 in six of ten
human sera (Fig. 4C) giving evidence for the presence of self-
epitopes in this region of CIV. Interestingly these six sera also
had positive titers against the collagen binding N-terminal M3-
fragment (M3.5) whereas vice versa sera with a negative titer
against CB3 did not possess M3.5-antibodies (Fig. 4D). Taken
together the results demonstrate that immunization of mice with
the collagen binding type specific N-terminal part of the M3-
protein (M3.5) generates immune response against the CB3-
region - its binding site in collagen IV. A similar immune
response was found in serum of patients, which indicates a role
of this response in the pathogenesis of ARF. The results
strongly suggest that binding of M3-protein induces structural
changes in the CB3-region rendering this region of CIV auto-
antigenic.
Discussion
ARF and subsequent RHD are serious autoimmune sequelae of
S. pyogenes infection, and previous studies have demonstrated that
the rheumatogenic potential of S. pyogenes strains is associated with
certain M-types [11]. M3 is one such rheumatogenic serotype and
it has been shown to interact with CIV, leading to the production
of auto-antibodies against collagen. High titers of CIV-reactive
antibodies in sera from patients with ARF are evidence for the
clinical relevance of CIV-autoimmunity [6]. Molecular mimicry
has been implicated in the induction of myosin auto-immunity
[12]. However, experimental data that indicate molecular mimicry
of the rheumatogenic serotype M3 are missing. The observation,
that CIV auto-antibodies which are induced in mice by injection
of collagen binding M-proteins do not cross-react with the
respective M-protein, points towards an influence of the M-
protein on the presentation of collagen as a self-antigen rather
than molecular mimicry [5,6]. The recent finding, that induction
of such an autoimmune response by collagen binding M-proteins
depends on the presence of the PARF motif, suggests a critical role
of collagen binding in this process [5].
Characterization of the interaction between CIV and M3-
protein by electron microscopy at the molecular level identified
two distinct binding sites on the CIV-molecule, one situated in the
CB3-region, which is known to bare the motif for interactions with
the A-domain of a1- and a2 integrin [9,10]. The cyanogen
bromide cleavage product CB3 is a disulfide-bonded heterotrimer
of two a1(IV) and two a2(IV) fragments. It retains a triple-helical
structure that is necessary for integrin binding [9,10]. The
structural requirements and influences of the interaction between
CB3 and streptococcal M-protein are not yet described but
promise to shed more light on its role in streptococcal
pathogenesis. The observation that M3-protein binds to the
integrin binding fragment of CIV suggests that it interferes with
CIV-integrin interactions, modulates them or exploits them for the
benefit of the bacterium. Experiments with the collagen-binding
M-protein of group G streptococci, FOG, indicate that the PARF-
motif is involved in the CB3-interaction (Fig. 3), which underscores
the importance of this motif in the interaction between
streptococcal M-proteins and CIV [5]. The lack of molecular
mimicry together with the data obtained on PARF-containing M-
proteins suggest that the herein described interaction evokes
autoantigenic properties of the CB3-region. Mice immunized with
the N-terminal CIV-binding fragment of M3 (M3.5) developed
CB3 auto-antibodies, indicating that the region bares a potent self-
epitope. Anti-CB3-titers in the sera of ARF patients demonstrate a
clinical relevance of this self-epitope. In this context, it is
noteworthy that another CIV-dependent autoimmune disease,
the Goodpasture Syndrome, is caused by exposure of cryptic
epitopes to the immune system [4], which fosters the notion of
PARF Binds CB3 of Collagen IV
PLoS ONE | www.plosone.org 2 March 2009 | Volume 4 | Issue 3 | e4666Figure 1. Electron microscopy of M3-CIV complexes. Micrographies (left panel) and corresponding cartoons (right panel) show complexes that
consist of M3-protein and CIV. Block arrows highlight M3-protein (depicted in gray in the cartoons), both free and bound to CIV (depicted in black in
the cartoons). Arrow heads point out the 7S regions of CIV, while line arrows points out the globular heads of the CIV molecules. The bars represent
100 nm in the representative overviev (A) and 50 nm in the panel of selected complexes (B).
doi:10.1371/journal.pone.0004666.g001
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Hence, further examination of the structural influences that are
exerted by the PARF-motif, when it is bound to CB3-region,
promise insights that are fundamental for the understanding of
collagen-dependent ARF.
Moreover, the identification of a smaller fragment of collagen as
a receptor for PARF is a considerable step ahead in the
development of a specific diagnostic test for rheumatogenic
streptococcal strains. Since only about 5% of all S. pyogenes strains
have the potential to cause ARF, their detection would identify the
relatively low proportion of patients – mostly children – that need
an intensive treatment to prevent the disease; a strategy with the
potential to improve the efficiency of prevention programs for
endemic areas, until an effective vaccine against S. pyogenes is
available.
Methods
Bacterial strains
Streptococci were routinely grown in Todd-Hewitt broth
supplemented with 5% Yeast extract (THY) or Tryptic Soy Broth
(TSB), with antibiotics where appropriate (3 mg/ml erythromycin
(Ery), 500 mg/ml kanamycin (Kan)) at 37uC without agitation.
E.coli strains used for overexpression of recombinant proteins were
grown at 37uC with agitation in Luria broth with appropriate
antibiotics (100 mg/ml ampicillin (Amp)).
Rotary metal shadowing transmission electron
microscopy of protein complexes
Complexes between M3-protein and collagen IV were analyzed
by mica sandwich squeezing/rotary shadowing and transmission
Figure 2. CB3 binding by M3-protein. (A) Interaction with
125I-CB3 was measured in a pull-down assay with, M3-GST (black bar), or M18-GST (grey
bar) protein coupled to glutathion sepharose beads. A control sample with glutathion separose alone (2) was included (white bar). (B) Binding of
125I-
CIV (black bars) or
125I-CB3 (grey bars)t oS. gordonii that heterologously expressed M3 protein on its surface (SGO M3) and that of the wild type
control (SGO) was expressed as a percentage of total radioactivity input. Error bars in A and B represent the standard deviation of the triplicate
measurements. (C and D) Surface plasmon resonance measurements of the interaction between M3-protein and immobilized CIV (C) or CB3 (D),
respectively. Injection of M3-protein at different concentrations (a: 50 mg/ml, b: 25 mg/ml, c: 12.5 mg/ml, d: 6.25 mg/ml) started at t=0 s and stopped
at t=120 s. The response is expressed in response units (RU).
doi:10.1371/journal.pone.0004666.g002
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PLoS ONE | www.plosone.org 4 March 2009 | Volume 4 | Issue 3 | e4666Figure 3. Binding of PARF mutants to CB3. (A) Dot blot experiment with
125I-CB3 as the soluble ligand. Dots 1–9 are the immobilized mutants of
M protein FOG (for description see table in B); dot 10 is recombinant wild type protein. Recombinant M3- (+) and M18-proteins (2) were used as
positive and negative control, respectively. The table in B allows to compare the experiment with previous data on full length collagen IV[5].
doi:10.1371/journal.pone.0004666.g003
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were dialyzed overnight against 0.2 M ammonium hydrogen
carbonate, pH 7.9, in a microdialysis apparatus (5–50 ml,
Biowerk). They were subsequently mixed with an equal volume
of 80% glycerol and squeezed between two freshly cleaved mica
pieces for 5 minutes. Specimens were dried at high vacuum for 1–
2 h and rotary shadowed at a 9u angle with 2 nm platinum/
carbon, followed by coating with 10 nm carbon at a 90u angle.
Replicas were floated off onto distilled water and picked up on 400
mesh copper grids and then examined in a Jeol JEM 1230 electron
microscope operated at 60 kV accelerating voltage and at
calibrated magnifications. Images were recorded with a Gatan
Multiscan 791 CCD camera.
Collagen binding assays
Human placental full length CIV (Sigma-Aldrich) or the CB3-
fragment that was prepared as described previously[13], were
labeled with
125I by the chloramine T method [14]. Approxi-
mately 14 ng of
125I-CIV or
125I-CB3 was added to 250 mlo f
bacterial suspension and incubated at room temperature for
45 min. The cells were harvested by centrifugation, the superna-
tant carefully aspirated and pellet-associated radioactivity mea-
sured using an automated Wallac gamma counter (Perkin Elmer,
Jugesheim, Germany). All measurements were carried out in
triplicates. The results were expressed as the percentage of input
radioactivity.
Cloning and expression of recombinant proteins
For generation of GST–M3-protein, emm3 was amplified from
the chromosomal DNA of the M3 strain via PCR using the
following primers: M3-1: 59GCA GAC AGT AGG ATC CGA
TGC AGG AGT G 39 (BamHI restriction site); M3-3: 59 GAG
CAG CTT CAA CGT CGA CTT TTG CTT GGC 39 (SalI
restriction site). Standard cloning techniques were used to generate
constructs in the pGEX6P-1 vector system (Amersham Biosciences
Europe GmbH, Freiburg, Germany). Proteins were expressed, and
purified under native conditions following the manufacturer’s
protocol.
Radioactive pull down experiments
Pull down experiments were performed by mixing 50 mg soluble
purified recombinant M3-GST or M18-GST fusion protein with
0.5 mg soluble radiolabeled cyanogen bromide fragment CB3 of
CIV in a total volume of 70 ml PBS. The mixture was incubated
Figure 4. CIV and CB3 specific serum responses. (A) Serum Ig response for CB3 in M3.5 immunized mice. Reactivity was determined for sera
from PBS-immunized (PBS) or M3-protein-immunized (M3.5) mice. The anti-CIV (black bars) and anti-CB3 titers (grey bars) measured in individual mice
immunized with M3.5 (M3.5 #) or PBS (PBS #) are compared in (B). (C) Anti-CB3 titer of individual patient sera. Titers are shown for each individual
serum collected from ARF/RHD patients (triangles), or healthy individuals (circles). The significance of the differences measured in A and C was
examined using the t-test. (D) The six sera of patients with CB3 autoimmunity (black bars) showed also reactivity against the collagen binding part of
M3-protein (M3.5) (grey bars). The horizontal line indicates the cut-off titer for M3.5 positive sera. Error bars represent the standard deviation of the
triplicate measurements in B an D.
doi:10.1371/journal.pone.0004666.g004
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sepharose solution in PBS. The samples were then incubated for
30 min at 22uC, then beads were washed 36 with 1 ml PBST,
precipitated, and the amount of sepharose bound CB3/M-protein
complex was determined by measuring the radioactivity of the
pellet in a Wallac gamma counter (Perkin Elmer, Jugesheim,
Germany).
Surface plasmon resonance measurements
Protein interactions were studied in a BIAcore 2000 system
(BIAcore AB) using 10 mM HEPES, 100 mM NaCl, pH=7.4 as
running buffer. A CM5 sensor chip was activated by a 4 min
injection of 0.05 M N-hydroxysuccinimid, 0.2 M N-ethyl-N-(3-
dime-thylaminopropyl)-carbodiimide hydrochloride in water. Col-
lagen IV from human placenta (Sigma, 1 mg/ml in 0.1 M NaAc)
or cyanogens bromide fragment CB3 of collagen type IV was
diluted 1:25 in 10 mM NaAc (pH=5.2). Injection of 3 ml at a flow
rate of 5 ml/min led to immobilization of 400 to 550 response units
(RU) of collagen IV. Residual reactive groups were inactivated by
a 6 min injection of 1 M ethanolamine, 0.1 M NaHCO3, 0.5 M
NaCl, 5 mM EDTA, pH=8.0. Surface regeneration was achieved
by injection of two 30 s pulses of 0.2% SDS in water. The
BIAevaluation 3.0 software was used for further analysis of the
data. Shown curves represent the difference between the signal of
the collagen-coupled surface and of a deactivated control surface
devoid of protein. They were further corrected by subtraction of
the curve that was obtained after injection of buffer alone. Buffer
injection led to responses less than 5 RU.
Construction of recombinant S. gordonii that expresses
M3-protein
M3-protein was heterologously expressed on the surface of S.
gordonii GP1221 using the host integration system described by
Oggioni and Pozzi [15]. The emm3 gene was amplified via PCR
using the primers M3-1 and M3-3 which are described above,
cloned into plasmid vector pSMB103 to give functional in frame
fusion with the signal sequence and the membrane anchor coding
regions of emm6 gene, and inserted via gene replacement as gene
cassette into a defined chromosomal locus of the S. gordonii
chromosome, resulting in surface expression of a functional full
length M3-protein. Surface expression of M3-protein was
examined by using antibodies specifically recognizing the N-
terminal part of the M3-protein.
Ligand overlay assay
The ligand overlay assay was performed by spotting the purified
wild type protein and mutants of the collagen binding M-protein
FOG (5 mg) [5] on nitrocellulose. The membrane was blocked for
1 h in PBS containing 5% skim milk followed by a 1-h incubation
with radiolabeled CB3-fragment (200,000 cpm) in PBST. After
five washing steps in PBST, filters were dried and placed on
radiographic films (Eastman Kodak Co.) for auto-radiography.
Immunization of mice and detection of antibodies
Pathogen free 6–7 week old female C3H/He mice were
immunized intra-peritoneally with 100 mg of a recombinant,
purified N-terminal fragment of M3-protein (M3.5) (n=5) or PBS,
suspended in 100 ml Freund’s incomplete adjuvant per dose at day
1, 7 and 14. At day 21, serum samples of each group were
collected, pooled, and tested by ELISA. All studies were approved
by the appropriate authorities (Niedersa ¨chsisches Landesamt fu ¨r
Verbraucherschutz und Lebensmittelsicherheit).
A capture ELISA was used to determine the presence of anti-
collagen antibodies in sera. Microtiter plates (Greiner, Frick-
enhausen, Germany) were coated overnight at 4uC with anti-
human CIV rabbit serum (Progen, Heidelberg, Germany) diluted
1:100 in coating buffer, and blocked with 2% bovine serumalbu-
min (BSA). Sera (diluted 1:50 to 1:50,000 in serial dilutions in PBS)
were added to wells and incubated over night at 4uC. After
washing, a 1:1000 dilution of horseradish peroxidase (HRP)
conjugated goat anti-mouse Ig (Jackson Laboratories) was added
and incubated for 1 h. Antibody binding was detected using 2,2-
azino-di-[3-ethylbenzthiazoline sulfonate] diammonium salt
(ABTS tablets, Boehringer, Mannheim, Germany) as substrate.
The absorbance was determined at 405 nm in triplicates.
To determine anti-CB3 antibody titers, 96-well plates (Greiner,
Frickenhausen, Germany) were coated overnight at 4uC with CB3
(2 mg/ml in PBS) and blocked with 2% bovine serum albumin
(BSA) in phosphate buffered saline (PBS) for 1 h at room
temperature. Sera (diluted 1:50 to 1:50,000 in serial dilutions in
PBS) were added to wells and incubated over night at 4uC.
Antibody binding was measured as described above.
Patient sera
Sera from ARF patients and healthy controls have been
described in [5]. To determine anti-CB3 or anti-M3.5 titer CB3
or M3.5-protein were immobilized overnight at 4uC followed by
blocking with 1% bovine serum albumin in PBST. Wells were
washed before human sera diluted 1:50 to 1:50,000 in serial
dilutions in PBS were added to wells and incubated over night at
4uC. After washing, a 1:5000 dilution of horseradish peroxidase
(HRP) conjugated rabbit anti-human Ig (Sigma) was added and
incubated for 1 h at 37uC. Antibody binding was detected using
2,2-azino-di-[3-ethylbenzthiazoline sulfonate] diammonium salt
(ABTS tablets, Boehringer, Mannheim, Germany) as substrate.
The absorbance was determined at 405 nm in triplicates.
To determine the presence of anti-collagen antibodies in sera a
capture ELISA was used. Microtiter plates (Greiner, Frickenhau-
sen, Germany) were coated overnight at 4uC with anti-human
CIV rabbit serum (Progen, Heidelberg, Germany). After washing
with PBST 1% bovine serum albumin in PBS was added to the
wells and incubated for 1.5 h at 37uC. Human sera (diluted 1:50 to
1:50,000 in serial dilutions in PBS) were added to wells and
incubated over night at 4uC. Antibody binding was measured as
described above. The highest titer found in symptom free donors
was defined as cut-off [5].
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